吉非替尼与多西紫杉醇二线治疗晚期非小细胞肺癌 |
| |
引用本文: | 钟巍,王孟昭,张力,张晓彤,李龙芸.吉非替尼与多西紫杉醇二线治疗晚期非小细胞肺癌[J].肿瘤学杂志,2009,15(6):508-511. |
| |
作者姓名: | 钟巍 王孟昭 张力 张晓彤 李龙芸 |
| |
作者单位: | 中国医学科学院中国协和医科大学北京协和医院,北京,100730 |
| |
摘 要: | 目的]分析比较吉非替尼与多西紫杉醇单药,在一线治疗失败的晚期非小细胞肺癌(NSCLC)患者中的有效性和安全性。方法]回顾性分析北京协和医院2002年4月1日~2006年6月1日期间标准一线化疗失败的78例晚期NSCLC患者的临床资料,患者接受吉非替尼口服或多西紫杉醇单药治疗,其中吉非替尼组44例.多西紫杉醇组34例。采用Kaplan—Meier方法和Log—Rank分析比较两组患者无疾病进展生存时间(PFS)和中位生存时间(MS)。结果]吉非替尼组客观有效率明显高于多西紫杉醇组,分别为29.5%和2.9%;疾病控制率相近,分别为72.7%和70.6%。吉非替尼组和多西紫杉醇组患者的MS分别为17.5个月(95%CI:9.3—25.7)和26.8个月(95%CI:15.1~38.51(Х^2=3.35,P=0.0672);中位PFS分别为9.8个月(95%CI:6.2~13.4)和4.4个月(95%CI:2.5~6.3)(Х^2=11.33,P=0.0008)。吉非替尼组和多西紫杉醇组1年生存率分别为56%和74%。多西紫杉醇组3/4级血液学毒性反应高达58.8%,吉非替尼组未观察到3/4级血液学毒性。结论]吉非替尼作为晚期NSCLC患者的二线治疗药物,客观有效率及PFS明显高于多西紫杉醇组,且有更高的安全性。
|
关 键 词: | 癌 非小细胞肺 吉非替尼 多西紫杉醇 |
Gefitinib and Docetaxol as Second-line Therapy for Patients with Advanced Non-small Cell Lung Cancer |
| |
Institution: | ZHONG Wei, WANG Meng-zhao, ZHANG Li, et al. (Peking Union Medical College Hospital, Peking Union Medical College and Chinese Aeademy of Medical Sciences, Beijing 100730, China) |
| |
Abstract: | Purpose] To compare the efficacy and safety of gefitinib and docetaxol as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC) in Peking Union Medical College Hospital. Methods ] From 2002-4-1 to 2006-6-1, 78 cases with advanced NSCLC patients, who failed to standard first-line chemotherapy, received oral gefitinib(n=44) or docetaxol single agent chemotherapy(n=34). Median survival (MS) was analysed with Kaplan-Meier and Log-Rank method. Results] Partial remission (PR) (29.5%) in gefitinib group was significantly higher than that in docetaxol group (2.9%); while disease control rate was similar, 72.7% and 70.6% respectively. MS was 17.5 months (95%CI:9.3-25.7) in gefitinib group and 26.8 months (95% CI:15.1- 38.5) in docetaxol group without significant difference(Х^2=3.35,P=0.0672). PFS in gefitinib group and in docetaxol group was 9.8 months (95% CI: 6.2-13.4) and 4.4 months (95%CI: 2.5-6.3) respectively, with significant difference (Х^2=11.33, P=0.0008). One-year survival rate in gefitinib group and in docetaxol group was 56% and 74% respectively. Severe toxicity was not found in gefitinib group, while grade 3/4 hematologic toxicity was 58.8% in docetaxol group. Conclusion] Gefitinib as second-line treatment for NSCLC may be well tolerated and has better PR and PFS. |
| |
Keywords: | carcinoma non-small-cell lung gefitinib docetaxol |
本文献已被 维普 万方数据 等数据库收录! |
|